Lyell Wealth Management LP Has $15.11 Million Stock Holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Lyell Wealth Management LP boosted its position in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 0.5% during the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 33,955 shares of the medical equipment provider’s stock after buying an additional 170 shares during the quarter. Intuitive Surgical makes up approximately 1.4% of Lyell Wealth Management LP’s holdings, making the stock its 18th largest holding. Lyell Wealth Management LP’s holdings in Intuitive Surgical were worth $15,105,000 as of its most recent filing with the SEC.

Several other large investors have also recently bought and sold shares of ISRG. Creekmur Asset Management LLC raised its position in shares of Intuitive Surgical by 200.0% during the 1st quarter. Creekmur Asset Management LLC now owns 63 shares of the medical equipment provider’s stock valued at $25,000 after acquiring an additional 42 shares during the last quarter. Ridgewood Investments LLC bought a new stake in shares of Intuitive Surgical during the 2nd quarter valued at $26,000. Able Wealth Management LLC bought a new stake in shares of Intuitive Surgical during the 4th quarter valued at $28,000. Delos Wealth Advisors LLC raised its position in shares of Intuitive Surgical by 380.0% during the 1st quarter. Delos Wealth Advisors LLC now owns 72 shares of the medical equipment provider’s stock valued at $29,000 after acquiring an additional 57 shares during the last quarter. Finally, LRI Investments LLC bought a new stake in shares of Intuitive Surgical during the 1st quarter valued at $30,000. Institutional investors and hedge funds own 83.64% of the company’s stock.

Insider Transactions at Intuitive Surgical

In other news, SVP Henry L. Charlton sold 40,243 shares of the stock in a transaction dated Friday, August 23rd. The shares were sold at an average price of $486.84, for a total transaction of $19,591,902.12. Following the completion of the transaction, the senior vice president now directly owns 3,001 shares in the company, valued at approximately $1,461,006.84. The transaction was disclosed in a document filed with the SEC, which is available at this link. In related news, SVP Henry L. Charlton sold 40,243 shares of the firm’s stock in a transaction dated Friday, August 23rd. The shares were sold at an average price of $486.84, for a total value of $19,591,902.12. Following the completion of the sale, the senior vice president now directly owns 3,001 shares in the company, valued at approximately $1,461,006.84. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Robert Desantis sold 238 shares of the firm’s stock in a transaction dated Tuesday, September 10th. The shares were sold at an average price of $477.50, for a total transaction of $113,645.00. Following the completion of the sale, the executive vice president now owns 5,506 shares of the company’s stock, valued at $2,629,115. The disclosure for this sale can be found here. Insiders sold a total of 50,555 shares of company stock worth $24,267,737 in the last three months. Insiders own 0.90% of the company’s stock.

Analyst Ratings Changes

Several analysts have commented on ISRG shares. BTIG Research upped their target price on shares of Intuitive Surgical from $469.00 to $494.00 and gave the company a “buy” rating in a research report on Wednesday, August 28th. Stifel Nicolaus upped their target price on shares of Intuitive Surgical from $430.00 to $475.00 and gave the company a “buy” rating in a research report on Friday, July 19th. The Goldman Sachs Group assumed coverage on shares of Intuitive Surgical in a research report on Thursday, May 30th. They issued a “buy” rating and a $500.00 price objective for the company. Evercore ISI lowered their price objective on shares of Intuitive Surgical from $425.00 to $410.00 and set an “in-line” rating for the company in a research report on Friday, July 19th. Finally, Citigroup upped their price objective on shares of Intuitive Surgical from $512.00 to $560.00 and gave the company a “buy” rating in a research report on Thursday, August 22nd. Six equities research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $446.45.

Intuitive Surgical Trading Down 0.8 %

Shares of NASDAQ ISRG opened at $489.86 on Friday. The firm has a market cap of $173.75 billion, a PE ratio of 88.42, a PEG ratio of 5.41 and a beta of 1.39. Intuitive Surgical, Inc. has a 1-year low of $254.85 and a 1-year high of $496.18. The company has a fifty day moving average price of $463.74 and a 200 day moving average price of $421.80.

Intuitive Surgical (NASDAQ:ISRG) last posted its quarterly earnings data on Thursday, July 18th. The medical equipment provider reported $1.78 EPS for the quarter, topping analysts’ consensus estimates of $1.54 by $0.24. Intuitive Surgical had a net margin of 27.65% and a return on equity of 13.04%. The company had revenue of $2.01 billion during the quarter, compared to the consensus estimate of $1.97 billion. During the same period in the prior year, the business posted $1.18 EPS. The company’s quarterly revenue was up 14.5% on a year-over-year basis. Equities research analysts forecast that Intuitive Surgical, Inc. will post 5.22 EPS for the current year.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.